Medytox, Daewoong’s Botox Strain Dispute Set To Simmer Until Commission Decision
The ongoing battle between Korea's Medytox and Daewoong Pharm over the source of the botulinum toxin strain in Daewoong’s product looks set to rumble on until a trade commission unveils the results of its probe next year.
You may also be interested in...
ITC Takes Medytox’s Hand In US Botulinum Case, Bans Daewoong’s Imports
USITC’s initial decision in the Medytox and Daewoong botulinum dispute is favorable to Medytox and poised to take a toll on the Korean firm and partner Evolus as they face a 10-year ban on imports of their product to the US.
Medytox Faces Botulinum Approval Cancellation Over Data Issues
Leading South Korean botulinum toxin company Medytox is facing substantial business risk as its Meditoxin product is suspended amid test result manipulation investigations.
With Jeuveau Approval, Evolus Will Focus On The Beauty Business To Gain Market Share
Evolus believes its focus on the beauty business will be a differentiator for its neurotoxin Jeuveau. The company will publish head-to-head results against Botox alongside the Spring 2019 launch and does not expect a new trade secrets complaint from Botox maker Allergan to delay its product.